Stereotactic body radiation therapy: A novel treatment modality

Simon S. Lo, Achilles J. Fakiris, Eric L. Chang, Nina A. Mayr, Jian Z. Wang, Lech Papiez, Bin S. Teh, Ronald C. McGarry, Higinia R. Cardenes, Robert D. Timmerman

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

Stereotactic body radiation therapy (SBRT) involves the delivery of a small number of ultra-high doses of radiation to a target volume using very advanced technology and has emerged as a novel treatment modality for cancer. The role of SBRT is most important at two cancer stages-in early primary cancer and in oligometastatic disease. This modality has been used in the treatment of early-stage non-small-cell lung cancer, prostate cancer, renal-cell carcinoma, and liver cancer, and in the treatment of oligometastases in the lung, liver, and spine. A large body of evidence on the use of SBRT for the treatment of primary and metastatic tumors in various sites has accumulated over the past 10-15 years, and efficacy and safety have been demonstrated. Several prospective clinical trials of SBRT for various sites have been conducted, and several other trials are currently being planned. The results of these clinical trials will better define the role of SBRT in cancer management. This article will review the radiobiologic, technical, and clinical aspects of SBRT.

Original languageEnglish (US)
Pages (from-to)44-54
Number of pages11
JournalNature Reviews Clinical Oncology
Volume7
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Radiotherapy
Neoplasms
Renal Cell Carcinoma
Prostatic Neoplasms
Therapeutics
Clinical Trials
Liver Neoplasms
Non-Small Cell Lung Carcinoma
Spine
Radiation
Technology
Safety
Lung
Liver

ASJC Scopus subject areas

  • Oncology

Cite this

Stereotactic body radiation therapy : A novel treatment modality. / Lo, Simon S.; Fakiris, Achilles J.; Chang, Eric L.; Mayr, Nina A.; Wang, Jian Z.; Papiez, Lech; Teh, Bin S.; McGarry, Ronald C.; Cardenes, Higinia R.; Timmerman, Robert D.

In: Nature Reviews Clinical Oncology, Vol. 7, No. 1, 01.2010, p. 44-54.

Research output: Contribution to journalArticle

Lo, SS, Fakiris, AJ, Chang, EL, Mayr, NA, Wang, JZ, Papiez, L, Teh, BS, McGarry, RC, Cardenes, HR & Timmerman, RD 2010, 'Stereotactic body radiation therapy: A novel treatment modality', Nature Reviews Clinical Oncology, vol. 7, no. 1, pp. 44-54. https://doi.org/10.1038/nrclinonc.2009.188
Lo, Simon S. ; Fakiris, Achilles J. ; Chang, Eric L. ; Mayr, Nina A. ; Wang, Jian Z. ; Papiez, Lech ; Teh, Bin S. ; McGarry, Ronald C. ; Cardenes, Higinia R. ; Timmerman, Robert D. / Stereotactic body radiation therapy : A novel treatment modality. In: Nature Reviews Clinical Oncology. 2010 ; Vol. 7, No. 1. pp. 44-54.
@article{fa59327c76db4d818b2c9f78d1c5463d,
title = "Stereotactic body radiation therapy: A novel treatment modality",
abstract = "Stereotactic body radiation therapy (SBRT) involves the delivery of a small number of ultra-high doses of radiation to a target volume using very advanced technology and has emerged as a novel treatment modality for cancer. The role of SBRT is most important at two cancer stages-in early primary cancer and in oligometastatic disease. This modality has been used in the treatment of early-stage non-small-cell lung cancer, prostate cancer, renal-cell carcinoma, and liver cancer, and in the treatment of oligometastases in the lung, liver, and spine. A large body of evidence on the use of SBRT for the treatment of primary and metastatic tumors in various sites has accumulated over the past 10-15 years, and efficacy and safety have been demonstrated. Several prospective clinical trials of SBRT for various sites have been conducted, and several other trials are currently being planned. The results of these clinical trials will better define the role of SBRT in cancer management. This article will review the radiobiologic, technical, and clinical aspects of SBRT.",
author = "Lo, {Simon S.} and Fakiris, {Achilles J.} and Chang, {Eric L.} and Mayr, {Nina A.} and Wang, {Jian Z.} and Lech Papiez and Teh, {Bin S.} and McGarry, {Ronald C.} and Cardenes, {Higinia R.} and Timmerman, {Robert D.}",
year = "2010",
month = "1",
doi = "10.1038/nrclinonc.2009.188",
language = "English (US)",
volume = "7",
pages = "44--54",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Stereotactic body radiation therapy

T2 - A novel treatment modality

AU - Lo, Simon S.

AU - Fakiris, Achilles J.

AU - Chang, Eric L.

AU - Mayr, Nina A.

AU - Wang, Jian Z.

AU - Papiez, Lech

AU - Teh, Bin S.

AU - McGarry, Ronald C.

AU - Cardenes, Higinia R.

AU - Timmerman, Robert D.

PY - 2010/1

Y1 - 2010/1

N2 - Stereotactic body radiation therapy (SBRT) involves the delivery of a small number of ultra-high doses of radiation to a target volume using very advanced technology and has emerged as a novel treatment modality for cancer. The role of SBRT is most important at two cancer stages-in early primary cancer and in oligometastatic disease. This modality has been used in the treatment of early-stage non-small-cell lung cancer, prostate cancer, renal-cell carcinoma, and liver cancer, and in the treatment of oligometastases in the lung, liver, and spine. A large body of evidence on the use of SBRT for the treatment of primary and metastatic tumors in various sites has accumulated over the past 10-15 years, and efficacy and safety have been demonstrated. Several prospective clinical trials of SBRT for various sites have been conducted, and several other trials are currently being planned. The results of these clinical trials will better define the role of SBRT in cancer management. This article will review the radiobiologic, technical, and clinical aspects of SBRT.

AB - Stereotactic body radiation therapy (SBRT) involves the delivery of a small number of ultra-high doses of radiation to a target volume using very advanced technology and has emerged as a novel treatment modality for cancer. The role of SBRT is most important at two cancer stages-in early primary cancer and in oligometastatic disease. This modality has been used in the treatment of early-stage non-small-cell lung cancer, prostate cancer, renal-cell carcinoma, and liver cancer, and in the treatment of oligometastases in the lung, liver, and spine. A large body of evidence on the use of SBRT for the treatment of primary and metastatic tumors in various sites has accumulated over the past 10-15 years, and efficacy and safety have been demonstrated. Several prospective clinical trials of SBRT for various sites have been conducted, and several other trials are currently being planned. The results of these clinical trials will better define the role of SBRT in cancer management. This article will review the radiobiologic, technical, and clinical aspects of SBRT.

UR - http://www.scopus.com/inward/record.url?scp=76849110200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76849110200&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2009.188

DO - 10.1038/nrclinonc.2009.188

M3 - Article

C2 - 19997074

AN - SCOPUS:76849110200

VL - 7

SP - 44

EP - 54

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 1

ER -